- Within the Biotechnology industry, companies specializing in developing products with Orphan Drug designation have become a popular business model.
- We believe investors overlook the difficulties in the Orphan Drug business, leading to excessive valuations. These are not simply drugs that get favorable treatment due to small markets.
- Aegerion launched Juxtapid/Lojuxta for a rare Orphan Disease in 2013. We view its current situation as an example of both the advantages and problems of Orphan Drug companies.